AMBS OTC
Amarantus BioScience Holdings, Inc.
1W: +0.0%
1M: +9900.0%
3M: +0.0%
YTD: +900.0%
1Y: -66.7%
3Y: -88.9%
5Y: -99.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$95K
+0.0% ▲
Gross Profit
$95K
+0.0% ▲
Operating Income
-$268K
-81.1% ▼
Net Income
-$5M
+53.3% ▲
EPS (Diluted)
$-0.01
+62.6% ▲
EBITDA
-$5M
+54.5% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $20M | $75K | $0 | $95K |
| YoY Growth | +0.0% | +0.0% | -99.6% | -100.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $20M | $75K | $0 | $95K |
| Gross Margin | — | 100.0% | 100.0% | — | 100.0% |
| R&D Expenses | $2K | $610 | $0 | $0 | $0 |
| SG&A Expenses | $3M | $2M | $702K | $148K | $363K |
| Operating Expenses | $3M | $2M | $702K | $148K | $363K |
| Operating Income | -$3M | $18M | -$628K | -$148K | -$268K |
| Operating Margin | — | 91.6% | -840.7% | — | -281.1% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$11M | $18M | -$628K | -$10M | -$5M |
| Tax Expense | -$3K | $0 | $0 | $0 | $0 |
| Net Income | -$11M | $18M | -$628K | -$10M | -$5M |
| Net Margin | — | 91.9% | -840.7% | — | -4995.2% |
| EPS (Diluted) | $-0.05 | $0.07 | $-0.00 | $-0.02 | $-0.01 |
| EBITDA | -$3M | $19M | -$422K | -$10M | -$5M |
| Shares Outstanding | 234M | 270M | 368M | 465M | 580M |